{"id":"https://openalex.org/W2114755668","doi":"https://doi.org/10.1517/13543784.11.6.837","title":"ZD1839: targeting the epidermal growth factor receptor in cancer therapy","display_name":"ZD1839: targeting the epidermal growth factor receptor in cancer therapy","publication_year":2002,"publication_date":"2002-06-01","ids":{"openalex":"https://openalex.org/W2114755668","doi":"https://doi.org/10.1517/13543784.11.6.837","mag":"2114755668","pmid":"https://pubmed.ncbi.nlm.nih.gov/12036427"},"language":"en","primary_location":{"id":"doi:10.1517/13543784.11.6.837","doi":"https://doi.org/10.1517/13543784.11.6.837","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.11.6.837","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008593691","display_name":"Roy S. Herbst","orcid":"https://orcid.org/0000-0003-2535-5847","observed_orcids":["https://orcid.org/0000-0003-2535-5847"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Roy S Herbst","raw_affiliation_strings":["Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA. rherbst@mail.mdanderson.org","Fax: +1 713 796 8655","MD Anderson Cancer Center, Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Blvd, Box 432, Houston, Texas 77030, USA, Tel: +1 713 792 6363"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA. rherbst@mail.mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Fax: +1 713 796 8655","institution_ids":[]},{"raw_affiliation_string":"MD Anderson Cancer Center, Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Blvd, Box 432, Houston, Texas 77030, USA, Tel: +1 713 792 6363","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5008593691"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":1.043,"has_fulltext":false,"cited_by_count":57,"citation_normalized_percentile":{"value":0.75738916,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"11","issue":"6","first_page":"837","last_page":"849"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.023000000044703484,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9810000061988831},{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor","display_name":"epidermal growth factor receptor","score":0.984000027179718},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9110000133514404},{"id":"https://openalex.org/keywords/erbb-receptor-family","display_name":"ErbB receptor family","score":0.6980000138282776},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8830000162124634},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5740000009536743},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.5789999961853027},{"id":"https://openalex.org/keywords/antitumour-activity","display_name":"antitumour activity","score":0.8220000267028809},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.6140000224113464},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.5519999861717224},{"id":"https://openalex.org/keywords/head-and-neck-cancer","display_name":"head and neck cancer","score":0.8619999885559082},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.8289999961853027},{"id":"https://openalex.org/keywords/colon-cancer","display_name":"colon cancer","score":0.9369999766349792},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":1.0}],"concepts":[{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.7033083438873291},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5442760586738586},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.49042436480522156},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.489836186170578},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.44057339429855347},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4392699897289276},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.4214283525943756},{"id":"https://openalex.org/C2776362946","wikidata":"https://www.wikidata.org/wiki/Q424374","display_name":"Epidermal growth factor","level":3,"score":0.41954505443573},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.36339712142944336},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3596333861351013}],"mesh":[{"descriptor_ui":"D000077156","descriptor_name":"Gefitinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018795","descriptor_name":"Device Approval","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1517/13543784.11.6.837","doi":"https://doi.org/10.1517/13543784.11.6.837","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.11.6.837","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},{"id":"pmid:12036427","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12036427","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on investigational drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":40,"referenced_works":["https://openalex.org/W27838513","https://openalex.org/W1590794385","https://openalex.org/W1939364580","https://openalex.org/W1969875009","https://openalex.org/W1970955548","https://openalex.org/W1977221327","https://openalex.org/W1980105739","https://openalex.org/W1980222559","https://openalex.org/W1983790923","https://openalex.org/W1985153867","https://openalex.org/W1988583852","https://openalex.org/W1999444744","https://openalex.org/W2010174111","https://openalex.org/W2011175733","https://openalex.org/W2014718897","https://openalex.org/W2058839845","https://openalex.org/W2062366098","https://openalex.org/W2064047613","https://openalex.org/W2075938486","https://openalex.org/W2081441817","https://openalex.org/W2081625464","https://openalex.org/W2088597803","https://openalex.org/W2092994996","https://openalex.org/W2093281866","https://openalex.org/W2095483608","https://openalex.org/W2114291028","https://openalex.org/W2118568339","https://openalex.org/W2120185850","https://openalex.org/W2130840817","https://openalex.org/W2131362842","https://openalex.org/W2132080332","https://openalex.org/W2135938911","https://openalex.org/W2142661339","https://openalex.org/W2143536404","https://openalex.org/W2153837633","https://openalex.org/W2155977433","https://openalex.org/W2163402367","https://openalex.org/W2167368130","https://openalex.org/W2275508015","https://openalex.org/W4244120980"],"related_works":["https://openalex.org/W4254591229","https://openalex.org/W2104431314","https://openalex.org/W2049938167","https://openalex.org/W4235470913","https://openalex.org/W2007314461","https://openalex.org/W2075425070","https://openalex.org/W2071040849","https://openalex.org/W2129040492","https://openalex.org/W2002859032","https://openalex.org/W2059942370"],"abstract_inverted_index":{"The":[0,22],"erbB":[1],"family":[2],"of":[3,19,41,71,100,144,167,188,219,223],"receptors,":[4],"which":[5],"includes":[6],"the":[7,42,162,220],"epidermal":[8,27,43,52],"growth":[9,28,44,53],"factor":[10,29,45,54],"receptor,":[11],"has":[12,33,93,121,133],"been":[13],"widely":[14],"implicated":[15,66],"in":[16,31,35,67,88,97,108,112,139,161,179],"promoting":[17,78],"proliferation":[18,68],"malignant":[20],"cells.":[21],"critical":[23],"role":[24],"played":[25],"by":[26],"receptor":[30,46],"cancer":[32,72,79,192],"resulted":[34],"extensive":[36],"research":[37],"for":[38],"selective":[39],"inhibitors":[40],"signalling":[47],"pathway.":[48],"Selective":[49],"small":[50],"molecule":[51],"receptor-tyrosine":[55],"kinase":[56],"inhibitors,":[57],"such":[58],"as":[59,185],"ZD1839":[60,120,132,178],"(Iressa),":[61],"block":[62],"signal":[63],"transduction":[64],"pathways":[65],"and":[69,74,87,111,124,156,164,193,205,209,211],"survival":[70],"cells":[73],"other":[75,91,201,212],"host-dependent":[76],"processes":[77],"cell":[80,169,190],"growth.":[81],"In":[82,129],"preclinical":[83],"studies,":[84,131],"ZD1839,":[85],"alone":[86],"combination":[89,180],"with":[90,114,141,181],"agents,":[92],"demonstrated":[94,158],"antitumour":[95,154],"activity":[96,138,155],"a":[98,142],"range":[99],"tumour":[101,145],"types.":[102,146],"Results":[103],"from":[104],"Phase":[105,148,172],"I":[106],"trials,":[107],"healthy":[109],"volunteers":[110],"patients":[113,140],"advanced":[115],"disease,":[116],"have":[117,157],"shown":[118,135],"that":[119],"excellent":[122],"bioavailability":[123],"an":[125,194,217],"acceptable":[126],"tolerability":[127],"profile.":[128],"these":[130],"also":[134],"promising":[136],"clinical":[137,196],"variety":[143],"Furthermore,":[147],"II":[149],"studies":[150],"confirmed":[151],"clinically":[152],"meaningful":[153],"symptom":[159],"relief":[160],"second-":[163],"third-line":[165],"treatment":[166,187],"non-small":[168,189],"lung":[170,191],"cancer.":[171],"III":[173],"trials":[174],"are":[175],"currently":[176],"evaluating":[177],"gemcitabine/cisplatin":[182],"or":[183],"paclitaxel/carboplatin":[184],"first-line":[186],"ongoing":[195],"trial":[197],"programme":[198],"is":[199],"investigating":[200],"tumours":[202],"(i.e.,":[203],"head":[204],"neck,":[206],"prostate,":[207],"colon":[208],"breast)":[210],"combinations.":[213],"This":[214],"article":[215],"provides":[216],"overview":[218],"current":[221],"profile":[222],"ZD1839.":[224]},"counts_by_year":[{"year":2018,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}